Back to search

Netherlands· NL-6cca64e0138b

Mepsevii 2 mg/ml concentraat voor oplossing voor infusie

A vestronidase alfa product containing vestronidase alfa, registered in Netherlands by Ultragenyx Germany GmbH. The same ATC class is registered in 10 of our 19 countries.

ATC A16AB18

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedMepsevii 2 mg/ml concentraat voor opl…ATCA16AB18REGISTER NO.NL-6cca64e0138bPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Vestronidase alfa is registered in 10 of 19 countries.

Countries holding a registration under ATC A16AB18 (vestronidase alfa), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose

Vestronidase alfa · ATC A16AB18

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
VESTRONIDASE ALFA
Manufacturer
Ultragenyx Germany GmbH
Country
Netherlands (NL)
ATC code
A16AB18
ATC class
Vestronidase alfa
Defined daily dose
20 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/18/1301

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Vestronidase alfa in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vestronidase alfa products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Mepsevii
  • Liechtenstein · Mepsevii
  • Norway · Mepsevii

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/39fd99f9-b52d-4abc-871a-af165d47d121
GET /v1/drugs/39fd99f9-b52d-4abc-871a-af165d47d121?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/mepsevii-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Vestronidase alfa",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp121008",
  "excipients": [
    "HISTIDINE, (L-)",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 2-WATER (E 339)",
    "POLYSORBAAT 20 (E 432)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "VESTRONIDASE ALFA"
  ],
  "leaflet_url": null,
  "authorised_at": "2018/08/23",
  "procedure_number": "EMEA/H/C/004438",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/18/1301",
  "additional_monitoring": "Y"
}

See everything about vestronidase alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.